阴道微粒化黄体酮预防妊娠期高血压疾病:系统综述与Meta分析
系统检索截至2023年6月20日的安慰剂对照随机试验,纳入11项RCT,评估阴道黄体酮对妊娠期高血压疾病(HDP)的影响。妊娠早期起始者降低HDP(RR 0.71,95%CI 0.53-0.93)和子痫前期(RR 0.61,95%CI 0.41-0.92)风险;中晚期起始者未见降低。
要点
- 妊娠早期起始阴道微粒化黄体酮降低HDP风险(RR 0.71,95%CI 0.53-0.93;中等确定性证据)。
- 妊娠早期起始阴道微粒化黄体酮降低子痫前期风险(RR 0.61,95%CI 0.41-0.92;中等确定性证据)。
- 妊娠中晚期起始阴道黄体酮与HDP及子痫前期降低无关(低确定性证据)。
核心结论
- 系统综述发现妊娠早期起始阴道微粒化黄体酮可能降低HDP和子痫前期风险。
研究设计与样本
- 检索Embase(OVID)、MEDLINE(OVID)、PubMed、CENTRAL和clinicaltrials.gov,自建库至2023年6月20日。
- 纳入阴道黄体酮预防或治疗妊娠并发症的安慰剂对照随机试验,定量合成11项RCT。
- 3项RCT在妊娠早期起始阴道黄体酮,8项在妊娠中晚期起始。
- 采用随机效应模型进行Meta分析,并使用GRADE方法评估证据确定性。
主要发现
- 妊娠早期起始阴道黄体酮 vs 安慰剂:HDP风险RR 0.71(95%CI 0.53-0.93,2项RCT,n=4431,I²=0%;中等确定性证据)。
- 妊娠早期起始阴道黄体酮 vs 安慰剂:子痫前期风险RR 0.61(95%CI 0.41-0.92,3项RCT,n=5267,I²=0%;中等确定性证据)。
- 妊娠中晚期起始阴道黄体酮 vs 安慰剂:HDP风险RR 1.19(95%CI 0.67-2.12,3项RCT,n=1602,I²=9%;低确定性证据)。
- 妊娠中晚期起始阴道黄体酮 vs 安慰剂:子痫前期风险RR 0.97(95%CI 0.71-1.31,5项RCT,n=4274,I²=0%;低确定性证据)。
关键数值与推荐
- 妊娠早期起始阴道微粒化黄体酮降低HDP风险(RR 0.71,95%CI 0.53-0.93;中等确定性证据)。
- 妊娠早期起始阴道微粒化黄体酮降低子痫前期风险(RR 0.61,95%CI 0.41-0.92;中等确定性证据)。
- 妊娠中晚期起始阴道黄体酮与HDP降低无关(RR 1.19,95%CI 0.67-2.12;低确定性证据)。
- 妊娠中晚期起始阴道黄体酮与子痫前期降低无关(RR 0.97,95%CI 0.71-1.31;低确定性证据)。
临床怎么用
- 作者认为妊娠早期起始阴道微粒化黄体酮可能降低HDP和子痫前期风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment with vaginal progesterone reduces the risk of miscarriage and preterm birth in selected high-risk women. The hypothesis that vaginal progesterone can reduce the risk of hypertensive disorders of pregnancy (HDP) is unexplored. OBJECTIVES: To summarise the evidence on the effectiveness of vaginal progesterone to reduce the risk of HDP. SEARCH STRATEGY: We searched Embase (OVID), MEDLINE (OVID), PubMed, CENTRAL and clinicaltrials.gov from inception until 20 June 2023. SELECTION CRITERIA: We included placebo-controlled randomised trials (RCTs) of vaginal progesterone for the prevention or treatment of any pregnancy complications. DATA COLLECTION AND ANALYSIS: We extracted absolute event numbers for HDP and pre-eclampsia in women receiving vaginal progesterone or placebo, and meta-analysed the data with a random effects model. We appraised the certainty of the evidence using GRADE methodology. MAIN RESULTS: The quantitative synthesis included 11 RCTs, of which three initiated vaginal progesterone in the first trimester, and eight in the second or third trimesters. Vaginal progesterone started in the first trimester of pregnancy lowered the risk of any HDP (risk ratio [RR] 0.71, 95% confidence interval [CI] 0.53-0.93, 2 RCTs, n = 4431 women, I2 = 0%; moderate-certainty evidence) and pre-eclampsia (RR 0.61, 95% CI 0.41-0.92, 3 RCTs, n = 5267 women, I2 = 0%; moderate-certainty evidence) when compared with placebo. Vaginal progesterone started in the second or third trimesters was not associated with a reduction in HDP (RR 1.19, 95% CI 0.67-2.12, 3 RCTs, n = 1602 women, I2 = 9%; low-certainty evidence) or pre-eclampsia (RR 0.97, 95% CI 0.71-1.31, 5 RCTs, n = 4274 women, I2 = 0%; low-certainty evidence). CONCLUSIONS: Our systematic review found first-trimester initiated vaginal micronised progesterone may reduce the risk of HDP and pre-eclampsia.
引用
- Melo P, Devall A, Shennan AH, et al. Vaginal micronised progesterone for the prevention of hypertensive disorders of pregnancy: A systematic review and meta-analysis. BJOG. 2023. PMID: 37941309. doi:10.1111/1471-0528.17705
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。